1 out of 5 biopsies fail to collect enough tissue to reach a diagnosis. Pathware has a point-of-care solution to verify biopsy quality during the procedure.
1 in 5 biopsies fail to make a diagnosis, forcing millions to undergo repeated procedures. At $3,100 per repeat procedure, this amounts to $2.7B lost by US hospitals annually. To address this issue, we developed the Bioptic platform; an automated biopsy assessment tool to verify the sample quality before the patient leaves. With 100% ownership of our IP, minimal regulatory risk, and 200 years experience in medical sales, we will launch in 2020.